natgillin/translations-raw huggingface dataset:
The pharmacokinetics of emtricitabine have not been studied in patients with varying degrees of hepatic insufficiency.
Farmakokinetika emtricitabina nije pacijenata u ispitanika s različitim stupnjevima jetrene insuficijencije.
The pharmacokinetics of emtricitabine have not been studied in subjects with hepatic impairment; however, emtricitabine is not significantly metabolised by liver enzymes, so the impact of liver impairment should be limited.
Farmakokinetika emtricitabina nije ispitana u ispitanika s oštećenjem funkcije jetre; meĎutim emtricitabin se neznatno metabolizira putem enzima jetre, pa bi učinak oštećenja funkcije jetre trebao biti ograničen.
The pharmacokinetics of emtricitabine, rilpivirine and tenofovir alafenamide have not been fully evaluated in patients co-infected with hepatitis B and/or C virus.
Farmakokinetika emtricitabina i tenofoviralafenamida nije potpuno procijenjena u bolesnika koji su istodobno zaraženi virusom hepatitisa B i/ili C.
The pharmacokinetics of enoxaparin have been studied on the basis of plasma levels of anti-Xa activity and activity of anti-IIb at the recommended doses following single and repeated subcutaneous administration, and following single intravenous injection.
Farmakokinetika enoksaparina ispitivana je na temelju razina anti-Xa aktivnosti i anti-IIb aktivnosti u plazmi, pri preporučenim dozama nakon jednokratne ili ponavljane supkutane primjene, i nakon jednokratne intravenske injekcije.
The pharmacokinetics of enzalutamide have been evaluated in prostate cancer patients and in healthy male subjects.
Farmakokinetika enzalutamida procijenjena je u bolesnika s karcinomom prostate i u zdravih muških ispitanika.
The pharmacokinetics of eptifibatide are linear and dose proportional for bolus doses ranging from 90 to 250 microgram/kg and infusion rates from 0.5 to 3.0 microgram/kg/min.
Farmakokinetika eptifibatida je linearna i odgovara dozi bolusa od 90 do 250 mikrograma/kg i brzini infuzije od 0,5 do 3,0 mikrogram/kg/min.
The pharmacokinetics of eptifibatide are linear and dose proportional for bolus doses ranging from 90 to 250 microgram/kg and infusion rates from 0.5 to 3.0 microgram/kg/min.
Farmakokinetika eptifibatida je linearna i odgovara dozi bolusa od 90 do 250 mikrograma/kg i brzini infuzije od 0,5 do 3,0 mikrograma/kg/min.
The pharmacokinetics of eptifibatide are linear and dose proportional for bolus doses ranging from 90 to 250 microgram/kg and infusion rates from 0.5 to 3.0 microgram/kg/min.
Farmakokinetika eptifibatida je linearna i proporcionalna dozi bolusa od 90 do 250 mikrograma/kg i brzini infuzije od 0,5 do 3,0 mikrograma/kg/min.
The pharmacokinetics of etravirine in 101 treatment-experienced HIV-1 infected paediatric patients, 6 years to less than 18 years of age and weighing at least 16 kg, showed that the administered weight-based dosages resulted in etravirine exposure comparable to that in adults receiving INTELENCE 200 mg b.i.d. (see sections 4.2 and 5.2) when administered at a dose corresponding to mg/kg b.i.d.
Farmakokinetika etravirina u 101 bolesnika zaraženog HIVom-1, koji su prethodno liječeni antiretrovirusnim lijekovima, u dobi od 6 godina do manje od 18 godina i težine barem 16 kg, pokazala je usporedive rezultate za izloženost etravirinu za dozu primijenjenu na temelju težine, u dozi koja odgovara 5,2 mg/kg b.i.d u odnosu na odrasle koji primaju INTELENCE 200 mg b.i.d. (vidjeti dijelove 4.2 i 5.2).
The pharmacokinetics of etravirine in paediatric patients less than 6 years of age are under investigation.
Farmakokinetika etravirina u pedijatrijskih bolesnika dobi manje od 6 godina je u fazi istraživanja.
The pharmacokinetics of fesoterodine have not been evaluated in paediatric patients.
Farmakokinetika fesoterodina nije ispitana u pedijatrijskih bolesnika.
The pharmacokinetics of flutemetamol (18F) in patients with renal or hepatic impairment has not been characterised.
Farmakokinetika flutemetamola (18F) u bolesnika s oštećenjem funkcije bubrega ili jetre nije opisana.
The pharmacokinetics of fondaparinux has not been studied in patients with severe hepatic impairment (see sections 4.2 and 4.4).
Farmakokinetika fondaparinuksa nije ispitivana u bolesnika s teškim oštećenjem jetre (vidjeti dio 4.2 i 4.4).
The pharmacokinetics of guanfacine is similar in children (aged 6 to 12) and adolescent (aged 13 to 17) ADHD patients, and healthy adult volunteers.
Farmakokinetika gvanfacina u djece (u dobi od 6 do 12 godina) i adolescenata (u dobi od 13 do 17 godina) s ADHD-om slična je onoj u zdravih, odraslih dobrovoljaca.
The pharmacokinetics of high dose thiotepa in children between 2 and 12 years of age do not appear to vary from those reported in children receiving 75 mg/m2 or adults receiving similar doses.
Farmakokinetika visokih doza tiotepe u djece u dobi između 2 i 12 godina se ne razlikuje od one koja je prijavljena u djece koja su primala 75 mg/m2 ili u odraslih kojima se daju slične doze.
The pharmacokinetics of icatibant has been extensively characterized by studies using both intravenous and subcutaneous administration to healthy volunteers and patients.
Farmakokinetika ikatibanta opsežno je opisana u ispitivanjima u kojima je ikatibant primijenjen intravenski i supkutano na zdravim dobrovoljcima i bolesnicima.
The pharmacokinetics of idelalisib in paediatric subjects have not been established (see section 4.2).
Farmakokinetika idelalisiba u pedijatrijskih ispitanika nije ustanovljena (vidjeti dio 4.2).
The pharmacokinetics of INCRELEX have not been studied in subjects greater than 65 years of age.
Farmakokinetika INCRELEXA nije ispitivana kod ispitanika starijih od 65 godina.
The pharmacokinetics of INCRELEX have not been studied in subjects younger than 12 years of age.
Farmakokinetika INCRELEXA nije ispitivana u ispitanika dobi mlađe od 12 godina.
The pharmacokinetics of intravenous busulfan was studied in 124 evaluable patients following a 2- hour intravenous infusion for a total of 16 doses over four days.
Farmakokinetika intravenskog busulfana ispitivana je na 124 bolesnika koje je bilo moguće ocijeniti nakon dvosatne intravenske infuzije ukupno 16 doza tijekom četiri dana.
The pharmacokinetics of IntronA were studied in healthy volunteers following single 5 million IU/m2 and 10 million IU doses administered subcutaneously, at 5 million IU/m2 administered intramuscularly and as a 30-minute intravenous infusion.
Farmakokinetika lijeka IntronA ispitivana je u zdravih dobrovoljaca nakon jedne supkutano primijenjene doze od 5 milijuna IU/m2 odnosno 10 milijuna IU, nakon intramuskularno primjenjene doze od 5 milijuna IU/m2 i nakon 30-minutne intravenske infuzije.
The pharmacokinetics of Kaletra 300/75 mg/m2 twice daily and 230/57.5 mg/m2 twice daily have been studied in a total of 53 paediatric patients, ranging in age from 6 months to 12 years.
Farmakokinetika lijeka Kaletra u dozi od 300/75 mg/m² dvaput na dan i 230/57,5 mg/m² dvaput na dan ispitana je u ukupno 53 pedijatrijska bolesnika u dobi od 6 mjeseci do 12 godina.
The pharmacokinetics of lacosamide has not been evaluated in severe hepatic impairment (see section 4.2).
Farmakokinetika lakozamida kod bolesnika s teškim oštećenjem jetre nije ispitana (vidjeti dio 4.2).
The pharmacokinetics of lacosamide has not been evaluated in severely hepatic impaired patients (see section 5.2).
Farmakokinetika lakozamida nije ispitana kod bolesnika s teškim oštećenjem jetre (vidjeti dio 5.2).
The pharmacokinetics of lamivudine are unaffected by hepatic impairment.
Oštećenje jetre ne utječe na farmakokinetiku lamivudina.
The pharmacokinetics of lapatinib were examined in patients with moderate (n = 8) or severe (n = 4) hepatic impairment (Child-Pugh scores of 7-9, or greater than 9, respectively) and in 8 healthy control patients.
Farmakokinetika lapatiniba ispitivana je u ispitanika s umjerenim (n=8) ili teškim (n=4) oštećenjem funkcije jetre (Child-Pugh zbroj 7-9, odnosno viši od 9) i u 8 zdravih kontrolnih ispitanika.
The pharmacokinetics of LEMTRADA has not been studied in patients aged 55 years and older.
Farmakokinetika lijeka LEMTRADA nije ispitivana u bolesnika u dobi od 55 godina i starijih.
The pharmacokinetics of LEMTRADA were evaluated in a total of 216 patients with RRMS who received intravenous infusions of either 12 mg/day or 24 mg/day for 5 consecutive days, followed by 3 consecutive days 12 months following the initial treatment course.
Farmakokinetika lijeka LEMTRADA ocijenjena je u ukupno 216 bolesnika s RRMS-om koji su primali intravenske infuzije u dozi od 12 mg/dan ili 24 mg/dan tijekom 5 uzastopnih dana, te zatim tijekom 3 uzastopna dana 12 mjeseci nakon prvog ciklusa liječenja.
The pharmacokinetics of levofloxacin following inhalation of Quinsair 240 mg twice daily were investigated in paediatric patients with CF aged 12 years and older and weighing ≥ 30 kg.
Farmakokinetika levofloksacina nakon inhalacije Quinsaira 240 mg dva puta na dan ispitivana je na pedijatrijskim bolesnicima s CF u dobi od 12 godina i starijih i s tjelesnom težinom ≥ 30 kg.
The pharmacokinetics of linagliptin has been extensively characterised in healthy subjects and patients with type 2 diabetes.
Farmakokinetika linagliptina je opsežno ispitana u zdravih ispitanika i bolesnika s dijabetesom tipa 2.
The pharmacokinetics of liraglutide was evaluated in patients with varying degree of hepatic impairment in a single­dose trial.
Farmakokinetika liraglutida procjenjivala se u bolesnika s različitim stupnjevima oštećenja jetre u ispitivanju s jednom dozom lijeka.
The pharmacokinetics of liraglutide was evaluated in subjects with varying degrees of hepatic impairment in a single-dose trial.
Farmakokinetika liraglutida procjenjivala se u ispitanika s različitim stupnjevima oštećenja jetre u ispitivanju s jednom dozom lijeka.
The pharmacokinetics of lurasidone in paediatric patients aged 6–17 years was generally comparable to those observed in adults.
Farmakokinetika lurasidona u pedijatrijskih bolesnika u dobi od 6 do 17 godina općenito je bila usporediva s onom opaženom u odraslih.
The pharmacokinetics of lurasidone is dose-proportional within a total daily dose range of 18.5 mg to 148 mg (equivalent to 20 to 160 mg lurasidone hydrochloride).
Farmakokinetika lurasidona proporcionalna je dozi u ukupnom dnevnom rasponu doza od 18,5 mg do 148 mg (što odgovara 20 do 160 mg lurasidonklorida).
The pharmacokinetics of macitentan and its active metabolite have mainly been documented in healthy subjects.
Farmakokinetika macitentana i njegovog aktivnog metabolita uglavnom je proučavana na zdravim ispitanicima.
The pharmacokinetics of miglustat is similar in adult type 1 Gaucher disease patients and Niemann-Pick type C disease patients when compared to healthy subjects.
Farmakokinetika miglustata slična je onoj u odraslih bolesnika s Gaucherovom bolesti tipa 1 i Niemann- Pickovom bolesti tipa C kada se usporedi sa zdravim osobama.
The pharmacokinetics of Myocet have not been specifically studied in patients with renal insufficiency.
Farmakokinetika Myoceta nije specifično proučavana u bolesnika s bubrežnom insuficijencijom.
The pharmacokinetics of naloxegol in the paediatric population has not been studied.
Farmakokinetika naloksegola u pedijatrijskoj populaciji nije ispitivana.
The pharmacokinetics of nelarabine and ara-G have not been specifically studied in renally impaired or haemodialysed patients.
U bolesnika u kojih postoji poremećaj bubrežne funkcije, odnosno bolesnika koji su na hemodijalizi, farmakokinetika nelarabina i ara-G nije specifično proučavana.
The pharmacokinetics of NovoMix 30 have not been investigated in older patients or in patients with renal or hepatic impairment.
Farmakokinetika lijeka NovoMix 30 nije ispitivana u starijih bolesnika niti u bolesnika s oštećenjem bubrega ili jetre.
The pharmacokinetics of NovoMix 50 have not been investigated in paediatrics, older patients or in patients with renal or hepatic impairment.
Farmakokinetika lijeka NovoMix 50 nije ispitivana u pedijatrijskoj populaciji, kao niti u starijih bolesnika i bolesnika s oštećenjem bubrega ili jetre.
The pharmacokinetics of NovoMix 70 have not been investigated in paediatrics, older patients or in patients with renal or hepatic impairment.
Farmakokinetika lijeka NovoMix 70 nije ispitivana u pedijatrijskoj populaciji, kao niti u starijih bolesnika i bolesnika s oštećenjem bubrega ili jetre.
The pharmacokinetics of Numient were evaluated following single doses in healthy subjects and following single and multiple doses in patients with Parkinson’s disease.
Farmakokinetika Numienta procijenjena je nakon pojedinačnih doza u zdravih ispitanika i nakon pojedinačnih i višestrukih doza u bolesnika oboljelih od Parkinsonove bolesti.
The pharmacokinetics of olanzapine are similar between adolescents and adults.
Farmakokinetika olanzapina je slična između adolescenata i odraslih.
The pharmacokinetics of omalizumab are linear at doses greater than 0.5 mg/kg.
Farmakokinetika omalizumaba linearna je pri dozama većima od 0,5 mg/kg.
The pharmacokinetics of opicapone was evaluated in elderly subjects (aged 65-78 years old) after 7- day multiple-dose administration of 30 mg.
Farmakokinetika opikapona procjenjivana je u starijih ispitanika (u dobi 65-78 godina) nakon višekratne primjene doze od 30 mg tijekom 7 dana.
The pharmacokinetics of oral contraceptives were unaffected by co-administration of CellCept (see also section 4.5).
Farmakokinetika oralnih kontraceptiva nije se izmijenila njihovom istodobnom primjenom s lijekom CellCept (vidjeti i dio 4.5).
The pharmacokinetics of oral contraceptives were unaffected by co-administration of mycophenolate mofetil (see also section 4.5).
Farmakokinetika oralnih kontraceptiva nije se izmijenila njihovom istodobnom primjenom sa mofetilmikofenolatom (vidjeti i dio 4.5).
The pharmacokinetics of oral topotecan has not been studied in patients with hepatic impairment (see section 4.2 and 4.4).
Farmakokinetika oralnog topotekana nije bila proučavana u bolesnika s oštećenjem jetre (vidjeti dio 4.2 i 4.4).
The pharmacokinetics of orally administered telmisartan are non-linear over doses from 20 – 160 mg with greater than proportional increases of plasma concentrations (Cmax and AUC) with increasing doses.
Farmakokinetika peroralno primijenjenog telmisartana nije linearna u dozama od 20-160 mg s više nego proporcionalnim povećanjem koncentracija u plazmi (Cmax i AUC) pri rastućim dozama.
The pharmacokinetics of orally administered telmisartan are non-linear over doses from 20 – 160 mg with greater than proportional increases of plasma concentrations (Cmax and AUC) with increasing doses.
Farmakokinetika peroralno primijenjenog telmisartana nije linearna u dozama od 20-160 mg s više nego proporcionalnim povećanjem koncetracija u plazmi (Cmax i AUC) pri rastućim dozama.
The pharmacokinetics of orally administered telmisartan are nonlinear over doses from 20-160 mg with greater than proportional increases of plasma concentrations (Cmax and AUC) with increasing doses.
Farmakokinetika peroralno primijenjenog telmisartana nije linearna u dozama od 20-160 mg s više nego proporcionalnim povećanjem koncetracija u plazmi (Cmax i AUC) pri rastućim dozama.
The pharmacokinetics of oritavancin in patients with severe hepatic impairment (Child-Pugh Class C) has not been evaluated.
Farmakokinetika oritavancina u bolesnika s teškim oštećenjem funkcije jetre (Child-Pugh stadij C) nije procijenjena.
The pharmacokinetics of oritavancin was examined in the single dose Phase 3 ABSSSI studies in patients with normal renal function, CrCL ≥90 mL/min (n=213), mild renal impairment,
Farmakokinetika oritavancina proučavana je u ispitivanjima akutnih bakterijskih infekcija kože i kožnih struktura faze 3 s jednom dozom u bolesnika s normalnom bubrežnom funkcijom,
The pharmacokinetics of oritavancin were evaluated in a study of subjects with moderate hepatic impairment (Child-Pugh Class B, n=20) and compared with healthy subjects (n=20) matched for gender, age and weight.
Farmakokinetika oritavancina procijenjena je u ispitanika s umjerenim oštećenjem funkcije jetre (Child-Pugh stadij B, n= 20) i uspoređena sa zdravim ispitanicima (n= 20) koji su odgovarali po spolu, dobi i tjelesnoj težini.
The pharmacokinetics of ospemifene has not been evaluated in patients with severe hepatic impairment (Child-Pugh Class score >9).
Farmakokinetika ospemifena nije ispitana u bolesnica s teškim oštećenjem jetre (Child-Pugh Class ljestvica >9).
The pharmacokinetics of ospemifene is only mildly affected by mild and moderate hepatic impairment (Child Pugh scores 5-9) when compared to healthy matched controls.
Na farmakokinetiku ospemifena samo blago utječe blago do umjereno oštećenje jetre (Child Plugh ljestvica 5-9) u usporedbi sa zdravim podudarnim osobama iz kontrolne skupine.
The pharmacokinetics of palifermin were studied in healthy volunteers and patients with haematological malignancies.
Farmakokinetička svojstva palifermina ispitivana su u zdravih dobrovoljaca i bolesnika s hematološkim malignim bolestima.
The pharmacokinetics of palonosetron or netupitant has not been studied in subjects with end-stage renal disease requiring hemodialysis and no data on the effectiveness or safety of Akynzeo in these patients are available.
Farmakokinetika palonozetrona ili netupitanta nije ispitana u bolesnika sa završnim stadijem bolesti bubrega kojima je potrebna hemodijaliza, te nema podataka o djelotvornosti ili sigurnosti Akynzea u tih bolesnika.
The pharmacokinetics of parathyroid hormone in patients with severe renal impairment (creatinine clearance of less than 30 mlmin) has not been investigated.
Farmakokinetika paratireoidnog hormon u bolesnika sa ozbiljnim oštećenjem bubrega (klirens kreatinina manji od 30 ml/min) nije ispitana.
The pharmacokinetics of PegIntron have not been evaluated in patients with severe hepatic dysfunction.
Farmakokinetika lijeka PegIntron nije se ispitivala u bolesnika s teškim oštećenjem jetrene funkcije.
The pharmacokinetics of pembrolizumab was studied in 2,856 patients with metastatic or unresectable melanoma, NSCLC, or carcinoma who received doses in the range of 1 to 10 mg/kg every 2 or weeks.
Farmakokinetika pembrolizumaba ispitivala se u 2856 bolesnika s metastatskim ili neresektabilnim melanomom, NSCLC-om ili karcinomom, koji su primali doze u rasponu od 1 do 10 mg/kg svaka 2 ili 3 tjedna.
The pharmacokinetics of perampanel have been studied in healthy adult subjects (age range 18 to 79), adults and adolescents with partial-onset seizures and primary generalised tonic-clonic seizures, adults with Parkinson’s disease, adults with diabetic neuropathy, adults with multiple sclerosis, and subjects with hepatic impairment.
Farmakokinetika perampanela ispitana je u zdravih odraslih ispitanika (raspon dobi od 18 do 79 godina), u odraslih i adolescenata s parcijalnim napadajima i primarno generaliziranim toničko-kloničkim napadajima, u odraslih s Parkinsonovom bolešću, odraslih s dijabetičkom neuropatijom, odraslih s multiplom sklerozom i ispitanika s oštećenjem funkcije jetre.
The pharmacokinetics of pioglitazone in children and adolescents < 18 years old has not been established.
Farmakokinetika pioglitazona u djece i adolescenata < 18 godina starosti nije ispitana.
The pharmacokinetics of Pixuvri was dose-independent in the 3 mg/m2 to105 mg/m2 dose range and no substantial differences were observed when the medicinal product was given as a single agent or in combination studies.
Farmakokinetička svojstva Pixuvria ovise o dozi u rasponu od 3 mg/m2 do 105 mg/m2 i nisu primijećene bitne razlike u ispitivanjima u kojima se lijek koristio kao monoterapija ili u kombinaciji s drugim lijekovima.
The pharmacokinetics of posaconazole are comparable in men and women.
Farmakokinetika posakonazola u žena usporediva je s onom u muškaraca.
The pharmacokinetics of posaconazole concentration for solution for infusion are comparable in men and women.
Farmakokinetika koncentrata za otopinu za infuziju u žena usporediva je s onom u muškaraca.
The pharmacokinetics of posaconazole tablets are comparable in men and women.
Farmakokinetika posakonazola tableta u žena usporediva je s onom u muškaraca.
The pharmacokinetics of radium-223 dichloride were linear in the activity range investigated (51 to 276 kBq/kg).
Farmakokinetika radij-223 diklorida bila je linearna u rasponu aktivnosti koji se ispitivao (51 do 276 kBq/kg).
The pharmacokinetics of raltegravir in infants under 4 weeks of age has not been established.
Nije utvrđena farmakokinetika raltegravira u dojenčadi mlađe od 4 tjedna.
The pharmacokinetics of regorafenib has not been studied in patients with severe renal impairment or end-stage renal disease.
Farmakokinetika regorafeniba nije ispitivana u bolesnika s teškim oštećenjem funkcije bubrega ili terminalnim stadijem bolesti bubrega.
The pharmacokinetics of regorafenib is not influenced by gender.
Spol ne utječe na farmakokinetiku regorafeniba.
The pharmacokinetics of repeated administrations of HEMANGIOL at 3 mg/kg/day given in 2 intakes has been investigated in 19 infants aged 35 to 150 days at the beginning of treatment.
Farmakokinetika ponovljenih primjena HEMANGIOL-a od 3 mg/kg/dnevno dana kroz 2 unosa ispitivana je kod 19 dojenčadi u dobi od 35 do 150 dana na početku liječenja.
The pharmacokinetics of reslizumab was not significantly different between males and females.
Farmakokinetika reslizumaba nije se značajno razlikovala između muškaraca i žena.
The pharmacokinetics of retigabine in children below 12 years of age have not been investigated.
Nije se ispitivala farmakokinetika retigabina u djece mlađe od 12 godina .
The pharmacokinetics of retigabine in children below 12 years of age have not been investigated.
Nije se ispitivala farmakokinetika retigabina u djece mlađe od 12 godina.
The pharmacokinetics of ribavirin and interferon alfa-2b (dose-normalized) are similar in adults and children or adolescents.
Farmakokinetika ribavirina i interferona alfa-2b (normalizirana po dozi) slična je u odraslih i djece ili adolescenata.
The pharmacokinetics of ribavirin are altered in patients with renal dysfunction due to reduction of apparent creatinine clearance in these patients (see section 5.2).
Farmakokinetika ribavirina promijenjena je u bolesnika s oštećenom funkcijom bubrega zbog smanjenog klirensa kreatinina u tih bolesnika (vidjeti dio 5.2).
The pharmacokinetics of rilpivirine and tenofovir disoproxil fumarate in children and adolescents are under investigation.
Farmakokinetika rilpivirina i tenofovirdizoproksilfumarata u djece i adolescenata još se ispituje.
The pharmacokinetics of rilpivirine have not been studied in patients with renal insufficiency.
Farmakokinetika rilpivirina nije ispitana u pacijenata s bubrežnom insuficijencijom.
The pharmacokinetics of rilpivirine in antiretroviral treatment-naïve HIV-1 infected adolescent subjects receiving EDURANT 25 mg once daily were comparable to those in treatment-naïve HIV-1 infected adults receiving EDURANT 25 mg once daily.
Farmakokinetika rilpivirina u adolescenata zaraženih virusom HIV-1 koji prethodno nisu bili liječeni antiretrovirusnim lijekovima i koji su primali EDURANT u dozi od 25 mg jedanput dnevno bila je usporediva s onom u odraslih zaraženih virusom HIV-1 koji prethodno nisu bili liječeni te su primali EDURANT u dozi od 25 mg jedanput dnevno.
The pharmacokinetics of rilpivirine in paediatric patients < 12 years of age is under investigation.
Farmakokinetika rilpivirina u pedijatrijskih bolesnika u dobi < 12 godina još se ispituje.
The pharmacokinetics of rituximab were assessed following two intravenous (IV) doses of 500 mg and 1000 mg on Days 1 and 15 in four studies.
Farmakokinetika rituksimaba ispitana je nakon dvije intravenske (i.v.) doze od 500 mg i 1000 mg, primijenjene 1. i 15. dana u četiri ispitivanja.
The pharmacokinetics of robenacoxib do not differ between male and female dogs, and are linear over the range 0.5–8 mg/kg.
Nema razlike između farmakokinetike robenakoksiba između ženki i mužjaka pasa te su u oba slučaja linearne u rasponu od 0,5 - 8 mg/kg.